Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Actinogen Medical is an Australian clinical-stage biotechnology company developing Xanamem, a selective 11β-HSD1 inhibitor targeting cortisol modulation for cognitive impairment in Alzheimer's disease and depression. The company is pre-revenue, burning approximately $8-10M annually, with clinical programs in Phase 2 trials evaluating cognitive endpoints in mild cognitive impairment and biomarker-driven patient selection strategies.
Actinogen operates a classic biotech development model: raise capital through equity offerings and grants, fund clinical trials to demonstrate safety/efficacy of Xanamem, then either out-license to large pharma partners for milestone payments and royalties, or commercialize independently if trials succeed. The company's value proposition centers on cortisol modulation as a novel mechanism for cognitive disorders, differentiated from amyloid-targeting approaches. Current cash runway estimated at 12-18 months based on burn rate, requiring additional capital raises before potential commercialization. No pricing power until regulatory approval achieved.
Phase 2 XanaMIA trial readouts for Xanamem in mild cognitive impairment - primary cognitive endpoints and biomarker data
Clinical trial enrollment milestones and patient recruitment rates for ongoing studies
Capital raising announcements - equity dilution events, warrant exercises, or non-dilutive funding (grants, partnerships)
Regulatory interactions - FDA/EMA feedback on trial design, IND approvals for new indications, or breakthrough therapy designations
Partnership or licensing deal announcements with pharmaceutical companies for development/commercialization rights
Clinical trial failure risk - Phase 2/3 trials have 30-40% success rates in CNS indications; negative efficacy or safety data would likely render Xanamem program worthless and trigger significant equity decline
Regulatory pathway uncertainty - FDA standards for cognitive endpoints in Alzheimer's are evolving; accelerated approval pathways require validated biomarkers that may not align with Xanamem's mechanism
Capital markets access risk - pre-revenue biotechs require continuous equity financing; market closures during risk-off periods could force unfavorable dilution or operational cuts
Crowded Alzheimer's landscape - competing against amyloid antibodies (Leqembi, Kisunla), tau-targeting therapies, and other novel mechanisms; differentiation requires clear efficacy advantage
Big pharma competition - large CNS-focused companies (Biogen, Eisai, Eli Lilly) have vastly superior resources for trial execution, regulatory navigation, and commercialization infrastructure
Mechanism validation risk - 11β-HSD1 inhibition is unproven in cognitive disorders; competitor failures in cortisol modulation could create negative sentiment overhang
Liquidity risk - estimated 12-18 month cash runway requires near-term capital raise; failure to secure funding would force wind-down or distressed sale
Dilution risk - equity raises at current $100M market cap with $8-10M annual burn implies 8-10% dilution per year minimum; clinical setbacks could force raises at depressed valuations with 30-50% dilution
Going concern risk - auditors may flag going concern issues if cash runway drops below 12 months without committed financing, triggering further stock pressure
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, capital raising ability is highly sensitive to risk appetite in biotech equity markets, which correlates with broader economic confidence. Severe recessions can freeze IPO/follow-on markets, creating liquidity crises for pre-revenue biotechs.
Rising rates negatively impact valuation through two channels: (1) higher discount rates applied to distant future cash flows (Xanamem revenue potentially 5-10 years out), compressing NPV of success scenarios, and (2) reduced investor appetite for speculative growth assets as risk-free rates increase, shifting capital toward yield-generating investments. Rate increases of 100-200bps can contract biotech valuations 20-40%.
minimal - Company operates on equity capital, not debt financing. Credit conditions affect ability to raise growth capital through equity markets (tighter credit reduces risk appetite for speculative biotech), but no direct exposure to credit spreads or refinancing risk given 0.18x debt/equity ratio.
growth - highly speculative, binary outcome profile attracts venture-style investors seeking 5-10x returns on clinical success. Typical holders include biotech-focused hedge funds, retail speculators, and thematic healthcare funds. Not suitable for value or income investors given no earnings, dividends, or tangible asset base. Momentum traders active around clinical catalysts.
high - clinical-stage biotechs exhibit 60-100% annualized volatility driven by binary trial outcomes, capital raise timing, and sector rotation. Single-day moves of 30-50% common on data releases. Recent 3-month decline of 22% followed by 6-month gain of 24% illustrates whipsaw potential. Beta to biotech sector likely 1.5-2.0x.